TLV Partners

#CISOs and security leaders attending RSA - this one’s for you. We’re taking over a private bowling venue for a select group of CISOs and leading Israeli founders. Expect sharp conversations, great food and drinks, and a bit of friendly competition on the lanes. 👉Tuesday, March 24 at 12:00 PM We’re down to our last few spots. If you’d like to join, reach out or register here: eu1.hubs.ly/H0sLb570

One of the advantages of being a disciplined generalist is perspective. Looking across multiple technology waves at the same time makes it easier to spot structural shifts early, connect signals across markets, and avoid getting locked into a single narrative. Many of our strongest investments began as insights in one domain that later became clear opportunities in another. In this interview with @Forbes, @brian_sack3 shares how this approach shapes the way we identify trends, work with founders, and think about timing, markets, and long-term conviction. Watch the full interview here: eu1.hubs.ly/H0rMt7d0

🎉 @CheckPointSW is acquiring @TeamCyata to accelerate its mission of delivering an end-to-end AI security platform for the agentic world. As AI systems shift from prompts to autonomous action, agents are already operating across browsers, IDEs, SaaS, and internal environments, often with limited visibility and control. Cyata built technology to discover, understand, and govern autonomous AI agents, with guardrails and posture controls designed specifically for this new layer. We are proud to have backed the Cyata team from day one, and to see their vision and technology become the foundation of Check Point’s AI security platform. @jifa @brian_sack3

Private AI research labs are becoming a major force in the industry. Some of the most talked-about AI companies today are raising significant funding with no product and no revenue, focusing instead on fundamental research and long-term breakthroughs. In this article, @YonatanMandelba shares his perspective on the convergence of research labs and venture-backed companies, and what this shift means for the future of the AI stack and for Israel’s ecosystem. Full article on @globesnews: eu1.hubs.ly/H0rGsCk0

Data centers, sovereign models, and AI integrity are emerging as key battlegrounds in the agent era of AI infrastructure. “The shift from training to inference to agents isn't just a change in bottlenecks. It's a change in the types of companies that will win,” says @YonatanMandelba. In this new article with @Calcalistech, Yonatan shares how the rise of agents is reshaping the AI stack and why this shift creates a major opportunity for Israeli startups. Read more on Ctech: eu1.hubs.ly/H0rz0Vz0

‼️ 🎤 New: The Art of Being a "Disciplined Generalist" in Investing Brian Sack, Partner at @TLV_Partners, shared how early-stage investing is about curiosity, bold ideas, and navigating the unknown. thespirocircle.com/p/the-art-of-b…

Venture capital is all about embracing ambiguity… but @TLV_Partners' Brian Sack has a hobby that flips the script. When he’s not evaluating early-stage startups, he’s practicing Hebrew calligraphy - a craft demanding extreme accuracy, patience, and focus. Discover more surprising sides of investors on the latest episode >>

Congrats to @Slice_Equity on raising a $25M Series A, led by @insightpartners, with participation from @TLV_Partners, Fenwick and Cooley LLP, R-Squared Ventures, and Jibe Ventures. As companies become global from day one, equity management has turned into one of the most complex and risk-heavy operational challenges across finance, legal, and HR. Slice is building AI-native, compliance-first infrastructure that enables companies to manage global equity from a single system, replacing fragmented tools, spreadsheets, and manual legal work. Already trusted by global leaders including @wiz_io, VAST Data, and Wayve, Slice is setting a new standard for how equity is managed across jurisdictions. Proud to have supported Slice from day one, and to continue backing @Maor_Levran, Yoel Amir, Samuel Amar, and the Slice team as they scale globally and build the next generation of equity infrastructure.

Excited to share the launch of CareBestie and their $4.4M Seed round, led by TLV Partners, with participation from outstanding healthcare founders and operators. CareBestie is building an AI powered, voice based engagement layer for home health and hospice, helping agencies stay continuously connected with patients between visits, at scale and without adding headcount. They are already working with leading home health agencies across the U.S., supporting more than 55,000 patients daily. We're proud to partner with Daniel Haven, David Ilievsky, and the CareBestie team as they bring a new model of patient engagement to an industry that needs it more than ever. @ShaharTzafrir

עוד צעד גדול לאדם, בעזרת AI. ♥️

From discovering novel CRISPR systems using machine learning to building a generative lab for drug discovery. @DovGertz, Co-founder and CEO of @Converge_Bio, sat down with @ShaharTzafrir to talk about his journey, the inflection point we are seeing in AI and biology, and what it really takes to turn AI from promise into real impact. They cover: • Why AI in biology is shifting from models to systems • How transformers, data scale and compute are reshaping drug discovery • What a “generative lab” alongside traditional wet labs really means • And what strong founder-investor partnerships look like in practice We are proud to be early partners to Dov, Oded Kalev and Iddo Weiner, and to continue supporting them as they push the frontier of AI and biology. Congratulations to the entire Converge team on the $25M Series A and the momentum behind it. Watch the full conversation: eu1.hubs.ly/H0qYq_v0

The conversation in AI drug discovery is finally shifting. From models to systems that actually work in the lab. Excited to share that @Converge_Bio has raised a $25M Series A to make generative AI usable across real biotech and pharma workflows. As the industry matures, platforms that integrate data, domain-specific models, frontier technology, and experimental validation will define the next decade of drug development. Converge is already proving this with real customers and real results. We’re proud to have backed @DovGertz, Oded Kalev and Iddo Weiner since the early days of Converge, and to continue supporting the team in their mission to make every biotech and pharma company an AI company. @ShaharTzafrir

The company today has raised $297M from investors @TLV_Partners and @ViolaGroup, among others. It has also secured partnerships with top pharmaceutical and academic centers such as @Teva @pfizer, and @AstraZeneca. thespirocircle.com/p/mapping-immu…